Does the media favor OVID or UNCY?

In the previous week, Unicycive Therapeutics had 22 more articles in the media than Ovid Therapeutics. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 6 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.02 indicating that Ovid Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ovid Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer UNCY or SPRY?

In the previous week, Unicycive Therapeutics had 6 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 22 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.05 beat Unicycive Therapeutics' score of 0.02 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral ARS Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, AVIR or UNCY?

Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Unicycive Therapeutics N/A N/A -$26.56M -$1.75 N/A

Is AVIR or UNCY more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Unicycive Therapeutics N/A -91.50% -61.47%

Does the media refer more to AVIR or UNCY?

In the previous week, Unicycive Therapeutics had 23 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 5 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.94 beat Unicycive Therapeutics' score of 0.02 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, UNCY or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Unicycive Therapeutics N/A N/A -$26.56M -$1.75 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is UNCY or RLMD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Relmada Therapeutics N/A -47.52% -43.97%

Does the media favor UNCY or RLMD?

In the previous week, Unicycive Therapeutics had 19 more articles in the media than Relmada Therapeutics. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 9 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.59 beat Unicycive Therapeutics' score of 0.02 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Relmada Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer CGC or UNCY?

Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 254.44%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media favor CGC or UNCY?

In the previous week, Unicycive Therapeutics had 22 more articles in the media than Canopy Growth. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 6 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.86 beat Unicycive Therapeutics' score of 0.02 indicating that Canopy Growth is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Canopy Growth 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Unicycive Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Unicycive Therapeutics (UNCY) Competitors

$5.29 -0.02 (-0.38%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.32 +0.03 (+0.60%)

As of 09/11/2026 07:55 PM Eastern

Compare

UNCY vs. OVID, SPRY, AVIR, RLMD, and CGC

Should you buy Unicycive Therapeutics stock or one of its competitors? Unicycive Therapeutics's main competitors and comparable companies include Ovid Therapeutics (OVID), ARS Pharmaceuticals (SPRY), Atea Pharmaceuticals (AVIR), Relmada Therapeutics (RLMD), and Canopy Growth (CGC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Unicycive Therapeutics had 22 more articles in the media than Ovid Therapeutics. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 6 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.02 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ovid Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Ovid Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	72.46	-$17.41M	-$0.31	N/A
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -23.64% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-23.64%	-20.52%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Ovid Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ovid Therapeutics presently has a consensus target price of $6.00, suggesting a potential upside of 123.05%. Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 254.44%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Ovid Therapeutics beats Unicycive Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

Unicycive Therapeutics (NASDAQ:UNCY) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Unicycive Therapeutics presently has a consensus target price of $18.75, indicating a potential upside of 254.44%. ARS Pharmaceuticals has a consensus target price of $26.40, indicating a potential upside of 454.62%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Unicycive Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A
ARS Pharmaceuticals	$116.93M	4.05	-$171.30M	-$2.18	N/A

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 6 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 22 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.05 beat Unicycive Therapeutics' score of 0.02 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Unicycive Therapeutics' return on equity of -91.50% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Summary

Unicycive Therapeutics beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Atea Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A

In the previous week, Unicycive Therapeutics had 23 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 5 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.94 beat Unicycive Therapeutics' score of 0.02 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Atea Pharmaceuticals presently has a consensus price target of $7.00, indicating a potential upside of 31.83%. Unicycive Therapeutics has a consensus price target of $18.75, indicating a potential upside of 254.44%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Atea Pharmaceuticals' return on equity of -64.25% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Summary

Atea Pharmaceuticals and Unicycive Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Unicycive Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 254.44%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 165.49%. Given Unicycive Therapeutics' higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Unicycive Therapeutics had 19 more articles in the media than Relmada Therapeutics. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 9 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.59 beat Unicycive Therapeutics' score of 0.02 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Relmada Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Relmada Therapeutics' return on equity of -47.52% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Relmada Therapeutics beats Unicycive Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Unicycive Therapeutics has lower revenue, but higher earnings than Canopy Growth. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$293.63M	1.42	-$190.29M	-$0.45	N/A
Unicycive Therapeutics	N/A	N/A	-$26.56M	-$1.75	N/A

Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 254.44%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Unicycive Therapeutics had 22 more articles in the media than Canopy Growth. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 6 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.86 beat Unicycive Therapeutics' score of 0.02 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Unicycive Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 0.4% of Canopy Growth shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Canopy Growth has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Unicycive Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Summary

Unicycive Therapeutics beats Canopy Growth on 9 of the 15 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$147.35M	$12.43B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-3.02	799.75	275.24	25.29
Price / Sales	N/A	763.36	655.99	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	3.75	10.39	10.33	6.20
Net Income	-$26.56M	$2.85B	$3.50B	$358.50M
7 Day Performance	2.52%	-3.61%	-3.32%	-2.35%
1 Month Performance	-1.86%	0.86%	-0.41%	-2.77%
1 Year Performance	36.69%	3.47%	19.21%	7.63%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	3.2179 of 5 stars	$5.29 -0.4%	$18.75 +254.4%	+29.3%	$147.35M	N/A	N/A	9	Trending News
OVID Ovid Therapeutics	2.6262 of 5 stars	$2.78 -0.9%	$5.86 +111.1%	+115.2%	$541.96M	$7.25M	N/A	60	News Coverage Positive News Analyst Forecast
SPRY ARS Pharmaceuticals	2.021 of 5 stars	$5.38 -4.4%	$26.40 +391.2%	-53.1%	$535.04M	$84.28M	N/A	90	Trending News Analyst Forecast
AVIR Atea Pharmaceuticals	2.3534 of 5 stars	$5.79 -0.7%	$7.00 +20.9%	+60.9%	$464.82M	N/A	N/A	70	News Coverage Positive News Analyst Upgrade
RLMD Relmada Therapeutics	2.9211 of 5 stars	$4.30 -2.9%	$12.00 +179.1%	+197.4%	$460.28M	N/A	N/A	10	News Coverage Positive News Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. OVID, SPRY, AVIR, RLMD, and CGC

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Summary

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Summary

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Summary

How does Unicycive Therapeutics compare to Canopy Growth?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. OVID, SPRY, AVIR, RLMD, and CGC

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Does the media favor OVID or UNCY?

Which has higher valuation & earnings, OVID or UNCY?

Is OVID or UNCY more profitable?

Which has more volatility & risk, OVID or UNCY?

Do insiders & institutionals have more ownership in OVID or UNCY?

Do analysts prefer OVID or UNCY?

Summary

How does Unicycive Therapeutics compare to ARS Pharmaceuticals?

Do analysts prefer UNCY or SPRY?

Which has better valuation & earnings, UNCY or SPRY?

Which has more volatility and risk, UNCY or SPRY?

Does the media prefer UNCY or SPRY?

Do insiders and institutionals have more ownership in UNCY or SPRY?

Is UNCY or SPRY more profitable?

Summary

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Which has more volatility & risk, AVIR or UNCY?

Which has better earnings and valuation, AVIR or UNCY?

Does the media refer more to AVIR or UNCY?

Do analysts rate AVIR or UNCY?

Do insiders & institutionals believe in AVIR or UNCY?

Is AVIR or UNCY more profitable?

Summary

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Do analysts rate UNCY or RLMD?

Does the media favor UNCY or RLMD?

Is UNCY or RLMD more profitable?

Which has stronger earnings and valuation, UNCY or RLMD?

Which has more volatility and risk, UNCY or RLMD?

Do insiders and institutionals hold more shares of UNCY or RLMD?

Summary

How does Unicycive Therapeutics compare to Canopy Growth?

Which has better earnings and valuation, CGC or UNCY?

Do analysts prefer CGC or UNCY?

Does the media favor CGC or UNCY?

Do insiders and institutionals hold more shares of CGC or UNCY?

Which has more risk & volatility, CGC or UNCY?

Is CGC or UNCY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools